Search clinical trials for: NSCLC, Immune Checkpoint inhibitor , PDL-1

Total 138727 results

Instituto Nacional de Cancerologia de Mexico

Unknown

Evaluation of PD1 / PDL1 Expression on Blood Cells & Tumor Tissue, Their Role as a Prognostic Target in NSCLC Patients

Non-Small Cell Lung Cancer

Mexico
RWJ Barnabas Health at Jersey City Medical Center

Unknown

Tumor Grade Determines PD-1/PDL-1 Expression

Ovarian Cancer | Endometrial Cancer

United States
3D Medicines (Sichuan) Co., Ltd.

Completed

Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors

Solid Tumors

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study

Non-small Cell Lung Cancer
Sorrento Therapeutics, Inc.

Withdrawn

Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors

Solid Tumor | Relapsed Solid Tumor | Refractory Tumor
Assiut University

Unknown

Immunohistochemical Assessment of Programmed Death ligand1 and LC3B in GBM

Glioblastoma Multiforme
VA Office of Research and Development
Oncovir, Inc.

Not yet recruiting

Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC (HAITEN-ICI)

Stage IV NSCLC

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

Prostatic Neoplasms

United States, Argentina, Australia, Austria, Brazil, Canada, Chile, China, Colombia, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, Russian Federation, Spain, Taiwan, United Kingdom
Merck Sharp & Dohme LLC

Terminated

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension

Prostatic Neoplasms

China
Merck Sharp & Dohme LLC

Recruiting

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

Esophageal Squamous Cell Carcinoma (ESCC)

Japan, Korea, Republic of, Taiwan, Thailand, France, Turkey, Italy, Switzerland, Brazil, Singapore, Germany, Chile, Norway
Merck Sharp & Dohme LLC

Recruiting

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Esophageal Squamous Cell Carcinoma

Japan, Korea, Republic of, Taiwan, China, Italy, Switzerland, Brazil, Germany, Singapore, Turkey, Thailand, Chile, Norway
Shenzhen Geno-Immune Medical Institute

Recruiting

Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas

Sarcoma | Ewing Sarcoma | Osteoid Sarcoma

China
Chinese PLA General Hospital

Not yet recruiting

Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC

Hepatocellular Carcinoma | Anlotinib | Thermal Ablation | PDL-1

China
University of Alabama at Birmingham

Not yet recruiting

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

Non Small Cell Lung Cancer

United States
Nantes University Hospital

Unknown

Bullous Pemphigoid Induced by antiPD-1/PDL-1 Therapy

Bullous Pemphigoid | Immunotherapy | Programmed Cell Death Ligand 1

France
Virginia Commonwealth University
National Cancer Institute (NCI)

Completed

SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx

Solid Tumor

United States
Tianjin Eye Hospital

Active, not recruiting

Myopia-control Efficacy by Peripheral Defocus Lens (PDL)

Myopia, Progressive

China
Harvard Pilgrim Health Care
Patient-Centered Outcomes Research Institute; Harvard School of Public Health... and other collaborators

Completed

Asthma in Families Facing Out-of-pocket Requirements With Deductibles (AFFORD)

Asthma

United States
University of Miami

Completed

Study of the Effects of the Pulsed-dye Laser at 585nm and 595nm to Treat Post-operative Scars on Suture-removal Day

Cicatrix | Scars

United States
Syneron Medical

Completed

Surgical Scar Treatment With the Pulsed Dye Laser in Combination With a CO2 Laser

Scars

United States
Academisch Medisch Centrum - Universiteit van Amsterdam...
UMC Utrecht

Completed

PDL-1 Targeting in Resectable Oesophageal Cancer (PERFECT)

Esophageal Cancer, Stage II | Esophageal Cancer Stage III

Netherlands
Sir Mortimer B. Davis - Jewish General Hospital

Recruiting

Montreal Immune-Related Adverse Events (MIRAE) Study (MIRAE)

Autoimmune Diseases | Cancer | Immune System Disorder | Inflammatory Reaction

Canada
Assiut University

Completed

The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer

Lung Cancer

Egypt
University of Jordan

Completed

PDL Anesthesia Versus Local Infiltration (PDL)

Anesthesia, Local
Central Hospital, Nancy, France

Unknown

Study of Polyfunctionality of Anti-tumor T Lymphocytes in Cancerology: Potential Biomarker for Emerging Immunotherapies (POLYTCANCER)

Cancer
Massachusetts General Hospital

Unknown

Pulsed-dye Laser Treatment Prior to Surgical Excision

Cicatrix

United States
Sohag University

Not yet recruiting

Expression of Programmed Death-1 (PD-1) & Programmed Death Ligand-1 (PDL-1) in Acute Lymphoblastic Leukemia in Pediatric

Acute Lymphoblastic Leukemia in Pediatric

Egypt
Istituto Scientifico Romagnolo per lo Studio e...

Recruiting

Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies (MESOVAX)

Progressive Disease | Mesothelioma, Malignant | Advanced Cancer | PD-L1 Negative

Italy
Bristol-Myers Squibb

Withdrawn

Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma (PD-L1)

Stage III or IV Melanoma
University of California, San Diego

Completed

Pilot Study of PDL to Treat BCC and SCCIS (PDLNMSC)

Basal Cell Carcinoma | Squamous Cell Carcinoma in Situ
Universitätsklinikum Hamburg-Eppendorf

Recruiting

KTP Laser vs Pulsed Dye Laser for Port-Wine Stains

Port-Wine Stain

Germany
Universitätsklinikum Hamburg-Eppendorf

Recruiting

Potassium Titanyl Phosphate Laser Versus Pulsed Dye Laser for Rosacea - a Prospective Study

Rosacea

Germany
University Hospital, Toulouse

Completed

PDL-1 Expression on Circulating Tumor Cells in Non-small Cell Lung Cancer (IMMUNO-PREDICT)

Lung Cancer

France
xjpfW
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; First Hospital... and other collaborators

Completed

The Role of Angiogenesis-related Pathways in the Development of Port Wine Stains

Port Wine Stain
Nasser Hanna, M.D.
Bristol-Myers Squibb; Hoosier Cancer Research Network

Terminated

Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor

Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

United States
Northwestern University

Completed

Comparison of Electrodessication, Potassium Titanyl Phosphate (KTP) Laser and Pulsed Dye Laser for Treatment of Cherry Angiomata

Cherry Angioma

United States
Merck Sharp & Dohme LLC
European Organisation for Research and Treatment of Cancer - EORTC; ETOP

Active, not recruiting

Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091) (PEARLS)

Non-small Cell Lung Cancer
University of Miami

Completed

Multiplex Laser vs. PDL (Pulsed Dye Laser ) in the Treatment of Surgical Scars

Scar

United States
Rigshospitalet, Denmark
Dana-Farber Cancer Institute; St. Jude Children's Research Hospital; European... and other collaborators

Completed

Second Malignant Neoplasms After Childhood ALL Therapy (PdL-SMN1)

Acute Lymphoblastic Leukemia

Denmark
Wissenschaftliches Institut Bethanien e.V
Merck Sharp & Dohme LLC; Institute of Pathology, University Clinic Düsseldorf

Completed

Sensitivity of PDL-1-analysis From Pleural Effusion in Non-small Cell Lung Cancer

Lung Neoplasms

Germany
West German Study Group
Merck Sharp & Dohme LLC; NanoString Technologies, Inc.

Completed

A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1) (Keyriched-1)

Breast Cancer

Germany
Academisch Medisch Centrum - Universiteit van Amsterdam...
University Medical Center Groningen; UMC Utrecht; Erasmus Medical Center; Catharina... and other collaborators

Recruiting

TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY (TAPESTRY)

Carcinoma, Squamous Cell | Oesophageal Cancer

Netherlands
Second Affiliated Hospital, School of Medicine,...

Recruiting

Pulsed Dye Laser and Intense Pulsed Light Configured With Different Wavelength Bands in Improving Erythematotelangiectatic Rosacea

Erythematotelangiectatic Rosacea

China
University of North Carolina, Chapel Hill

Withdrawn

Laser Induced Bioengineered Remodeling of Thermally Injured Skin Trial (LIBERTI)

Hypertrophic Scars
British Columbia Cancer Agency
Ozmosis Research Inc.

Unknown

PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

Canada
PDL BioPharma, Inc.

Completed

Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy

Melanoma | Metastases

United States
PDL BioPharma, Inc.

Terminated

A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis

Arthritis, Rheumatoid

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | TNBC - Triple-Negative Breast Cancer

United States
PDL BioPharma, Inc.

Completed

Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis

United States, Canada
Ain Shams University

Completed

Success Rate of 4 Injection Protocols for Mandibular First Molars With Symptomatic Irreversible Pulpitis

Root Canal Infection

Egypt

Search clinical trials for: NSCLC, Immune Checkpoint inhibitor , PDL-1

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations